This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional cancer ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The anticipated start of a Phase 2a clinical trial for VAR 200 in diabetic kidney disease by Q1 2025 demonstrates progress in their drug development pipeline, potentially leading to new treatment ...

This funding will advance its drug development pipeline, with a focus on CannEpil® and its clinical studies, and supports strategic operational reviews for long-term sustainability, including ...

This acceptance marks a significant advancement for the company in its drug development pipeline, potentially enhancing its position in the oncology pharmaceutical market. More about Shanghai ...

Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial ...